Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.85 Insider Own59.05% Shs Outstand8.38M Perf Week-16.57%
Market Cap13.00M Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float3.77M Perf Month-4.73%
Income-7.24M PEG- EPS next Q-0.20 Inst Own1.29% Short Float / Ratio1.21% / 3.76 Perf Quarter-15.57%
Sales0.32M P/S40.63 EPS this Y58.01% Inst Trans- Short Interest0.05M Perf Half Y-30.54%
Book/sh0.76 P/B1.86 EPS next Y-27.63% ROA-59.69% Target Price- Perf Year-46.79%
Cash/sh0.49 P/C2.88 EPS next 5Y- ROE-73.89% 52W Range0.95 - 3.99 Perf YTD-11.88%
Dividend- P/FCF- EPS past 5Y- ROI-87.94% 52W High-64.66% Beta3.82
Dividend %- Quick Ratio3.06 Sales past 5Y0.00% Gross Margin42.66% 52W Low47.67% ATR0.12
Employees14 Current Ratio3.07 Sales Q/Q25855.13% Oper. Margin-2256.55% RSI (14)46.84 Volatility6.48% 6.92%
OptionableNo Debt/Eq0.24 EPS Q/Q55.19% Profit Margin-2251.53% Rel Volume3.07 Prev Close1.52
ShortableYes LT Debt/Eq0.18 EarningsNov 14 AMC Payout- Avg Volume12.11K Price1.41
Recom- SMA20-3.98% SMA501.07% SMA200-15.80% Volume37,110 Change-7.24%
Dec-05-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 08:00AM
Nov-15-23 08:00AM
Nov-14-23 04:01PM
08:00AM Loading…
Nov-06-23 08:00AM
Oct-10-23 08:00AM
Sep-21-23 09:35AM
Sep-19-23 08:00AM
Sep-07-23 08:00AM
Aug-14-23 05:03PM
Jul-12-23 08:00AM
Jun-15-23 08:00AM
May-22-23 08:00AM
May-15-23 08:00AM
08:00AM Loading…
May-01-23 08:00AM
Apr-25-23 08:00AM
Apr-05-23 08:00AM
Mar-31-23 05:52PM
Mar-28-23 08:00AM
Mar-24-23 08:00AM
Feb-13-23 08:00AM
Jan-24-23 08:00AM
Jan-04-23 08:00AM
Dec-19-22 11:33AM
Dec-15-22 08:30AM
Dec-01-22 08:00AM
Nov-14-22 07:30AM
Nov-10-22 08:15AM
Nov-08-22 08:00AM
09:15AM Loading…
Oct-25-22 09:15AM
Oct-12-22 08:15AM
Sep-28-22 08:15AM
Sep-14-22 08:15AM
Sep-06-22 01:54PM
Sep-01-22 12:32PM
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.